Nob Hill Therapeutics
Nob Hill Therapeutics is part of the VIC Technology Venture Development ecosystem, focusing on developing innovative pulmonary and respiratory treatments and technologies, including the DryNeb dry powder nebulizer platform and therapeutics for lung-related diseases. The company aims to improve drug delivery efficiency, minimize side effects, and advance treatments for various pulmonary conditions.
Industries
Nr. of Employees
small (1-50)
Nob Hill Therapeutics
5901 Indian School Road, Suite 209 | Albuquerque, NM 87110
Products
Dry powder nebulizer platform
A dry powder nebulizer platform designed to disperse powdered drug independently of patient inspiratory effort and to emit dose only during inhalation, enabling efficient deposition to the lower respiratory tract and suitability for high-dose delivery.
Dry powder nebulizer platform
A dry powder nebulizer platform designed to disperse powdered drug independently of patient inspiratory effort and to emit dose only during inhalation, enabling efficient deposition to the lower respiratory tract and suitability for high-dose delivery.
Services
End-to-end development services for inhaled therapeutics including device integration, formulation development, preclinical testing, and regulatory preparation (pre-IND interactions and grant support).
End-to-end development services for inhaled therapeutics including device integration, formulation development, preclinical testing, and regulatory preparation (pre-IND interactions and grant support).
Expertise Areas
- Pulmonary drug delivery
- Dry powder inhalation technology
- Drug–device combination development
- Inhalation formulation development (small molecules and biologics)
Key Technologies
- Dry powder nebulizer platforms
- Aerosol generation independent of patient inhalation
- High-dose pulmonary aerosol delivery
- Dry powder formulation for biologics and small molecules
News & Updates
Announcement of two prominent experts joining the company's Strategic Advisory Board, Dr. Mark Parry-Billings and Dr. Scott L. Shofer.
The company announced a $3 million Series A financing round led by Tramway Venture Partners, with investments from TCA Venture Group and VIC Technology Venture Development.
Received a grant of up to $2M to develop an inhaled therapy for lung cancer.
The company was selected to present at the ATS 2023 Respiratory Innovation Summit.
Announcement of two prominent experts joining the company's Strategic Advisory Board, Dr. Mark Parry-Billings and Dr. Scott L. Shofer.
The company announced a $3 million Series A financing round led by Tramway Venture Partners, with investments from TCA Venture Group and VIC Technology Venture Development.
Received a grant of up to $2M to develop an inhaled therapy for lung cancer.
The company was selected to present at the ATS 2023 Respiratory Innovation Summit.